Jump to content

Coming Soon Clinical Vaccine trial


Recommended Posts

Medical Marketing to get US patent for anti-cancer vaccine technology

LONDON (AFX) - Medical Marketing International Group PLC said the US Patent and Trademark Office is to grant it a patent for the group's anti-cancer technology, following payment of standard fees.

The new patent covers the use of a novel genetic adjuvant that has been shown to enhance the anti-cancer activity of DNA vaccines, the company said.

This technology was granted a European patent in June 2006.

MMI's DNA vaccine technologies are already in clinical trials covering around 75 pct of the most serious cancers, including lung, colon and prostate, and the first clinical trials for infectious diseases are expected in 2007.

Chairman David Best said 'DNA vaccines have the potential to address major diseases in major global markets. This new patent protects a critical technical enhancement that makes DNA vaccines more effective and therefore, increases considerably the commercial value of our technology and the potential return to investors.'

newsdesk@afxnews.com slm

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.